tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Roivant Sciences placed on ‘Positive Catalyst Watch’ at JPMorgan

JPMorgan analyst Brian Cheng placed Roivant Sciences (ROIV) on “Positive Catalyst Watch” while keeping an Overweight rating on the shares with a $16 price target The firm expects brepocitinib’s pivotal readout in dermatomyositis to occur in the early part of the back half of the year. It believes brepocitinib’s mechanism of action is already de-risked based on published case studies. JPMogan thinks the drug will become the preferred JAKi in a major portion of the dermatomyositis market.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1